Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)

NCT04564339 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

123

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor Decision.

Conditions

Lupus Nephritis
Immunoglobulin A Nephropathy

Interventions

DRUG: Ravulizumab
DRUG: Placebo
OTHER: Background Therapy

Sponsor

Alexion Pharmaceuticals, Inc.